Wellington Management Group LLP Akebia Therapeutics, Inc. Transaction History

Wellington Management Group LLP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.32 - $0.67 $101,396 - $212,298	-316,863 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$0.72 - $2.93 $2,016 - $8,206	2,801 Added 0.89%	316,863 $227,000
Q4 2021 Feb 11, 2022	BUY	$2.26 - $3.34 $709,780 - $1.05 Million	314,062 New	314,062 $710,000
Q3 2021 Nov 15, 2021	SELL	$2.35 - $3.88 $25.2 Million - $41.7 Million	-10,736,859 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$2.83 - $4.2 $286,695 - $425,485	-101,306 Reduced 0.93%	10,736,859 $40.7 Million

Q1 2021 May 17, 2021	SELL	$2.92 - $5.06 $5.12 Million - $8.87 Million	-1,752,298 Reduced 13.92%	10,838,165 $36.7 Million
Q4 2020 Feb 12, 2021	BUY	$2.22 - $3.78 $10.4 Million - $17.6 Million	4,665,491 Added 58.87%	12,590,463 $35.3 Million
Q3 2020 Nov 16, 2020	BUY	$2.39 - $13.08 $1.55 Million - $8.51 Million	650,249 Added 8.94%	7,924,972 $19.9 Million
Q2 2020 Aug 14, 2020	BUY	$6.67 - $13.58 $37 Million - $75.4 Million	5,549,182 Added 321.59%	7,274,723 $98.8 Million
Q1 2020 May 14, 2020	BUY	$4.1 - $10.24 $3.4 Million - $8.49 Million	828,814 Added 92.43%	1,725,541 $13.1 Million
Q4 2019 Feb 11, 2020	BUY	$3.16 - $6.73 $2.83 Million - $6.03 Million	896,727 New	896,727 $5.67 Million

127

56.7M

937K

743K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $188M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

Stay updated on Wellington Management Group LLP with notifications on news.